Abstracts Archive - Page 860 of 2425 - ACR Meeting Abstracts

Abstract Number: 1524 • 2019 ACR/ARP Annual Meeting
Tildrakizumab Efficacy on Psoriasis in Patients with Psoriatic Arthritis—An Analysis from a Phase 2 Study
Alice Gottlieb ¹, Ana-Maria Orbai ², Rocco Ballerini ³, Richard C. Chou ⁴, Stephen Rozzo ³, Alan Mendelsohn³ and Luis R. Espinoza ⁵, ¹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York City, NY, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁴University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁵Section of Rheumatology, LSU Health Sciences Center, New Orleans, LA, New Orleans, LA
Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody approved by the FDA to treat moderate-to-severe plaque psoriasis. A randomized, double-blind, multidose, placebo-controlled, phase 2b…
Abstract Number: 1525 • 2019 ACR/ARP Annual Meeting
Safety of Tildrakizumab in Psoriatic Arthritis: An Interim Analysis from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial
Christopher Ritchlin ¹, Vibeke Strand ², Rocco Ballerini ³, Richard C. Chou ⁴, Stephen Rozzo ³, Alan Mendelsohn³ and Arthur Kavanaugh ⁵, ¹Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY, ²Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA, Palo Alto, CA, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁴University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁵University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: Tildrakizumab (TIL) is an anti–interleukin-23p19 monoclonal antibody approved by the FDA for treatment of moderate-to-severe plaque psoriasis1,2 and is under investigation for treatment of…
Abstract Number: 1526 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Tildrakizumab 100 Mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in a Phase 3 Study
Wendy Cantrell ¹, Patricia Lee ², Emil Tanghetti ³, Alan Mendelsohn⁴, Jeff Parno ⁴, Stephen Rozzo ⁴ and Wilson Liao ⁵, ¹Department of Dermatology, University of Alabama Birmingham, Birmingham, AL, USA; Dermatology at the Whitaker Clinic, Birmingham, AL, USA, Birmingham, AL, ²Center for Clinical Studies, Webster, TX, USA, Webster, TX, ³Center for Dermatology and Laser Surgery, Sacramento, CA, USA, Sacramento, CA, ⁴Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁵Department of Dermatology, University of California San Francisco, San Francisco, CA, USA, San Francisco, CA
Background/Purpose: We assessed residual plaque psoriasis in patients successfully treated with anti–interleukin-23p19 monoclonal antibody tildrakizumab (TIL) who interrupted treatment, relapsed, and were retreated vs continuously…
Abstract Number: 1527 • 2019 ACR/ARP Annual Meeting
Limited Changes in Hematological Parameters During Tildrakizumab Treatment: Post Hoc Analysis of Data from the Tildrakizumab Psoriasis Clinical Program
Holly Glover ¹, Kristine Kucera ², Alan Mendelsohn³, Jeff Parno ³, Stephen Rozzo ³, Frank Ferritto ⁴ and Renata Block ⁵, ¹Dermatology and Skin Cancer Surgery Center, McKinney, TX, USA, McKinney, TX, ²North Texas Dermatology, Richardson, TX, USA, Richardson, TX, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁴Polley Dermatology, Wilson, NC, USA, Wilson, NC, ⁵Pinski Dermatology & Cosmetic Surgery, Chicago, IL, USA, Chicago, IL
Background/Purpose: Tildrakizumab (TIL) is a high-affinity, anti–interleukin‐23p19 monoclonal antibody with demonstrated efficacy for the treatment of chronic plaque psoriasis in a phase 2b (P05495 [NCT01225731])…
Abstract Number: 1528 • 2019 ACR/ARP Annual Meeting
Resolution of Enthesitis and Dactylitis Is Maintained over Two Years of Ixekizumab Treatment in Patients with Psoriatic Arthritis
Arthur Kavanaugh¹, Lihi Eder ², Josef Smolen ³, Matthew M. Hufford ⁴, Chen-Yen Lin ⁴, Aubrey Trevelin Sprabery ⁴ and Dennis McGonagle ⁵, ¹University of California, San Diego School of Medicine, La Jolla, CA, ²Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, ³Medical University of Vienna, Vienna, Austria, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵University of Leeds, Leeds, United Kingdom
Background/Purpose: Enthesitis and dactylitis are prominent peri-articular domains of involvement in PsA.1 The activity of enthesitis and dactylitis can vary over time.1 Some conventional and…
Abstract Number: 1529 • 2019 ACR/ARP Annual Meeting
The Efficacy and Safety of Anti-TNFα Treatment in Ankylosing Spondylitis Patients with Late Onset Compared to Those with Adult Onset; The Data from TURKBIO Registry
Sadettin Uslu¹, Gercek Can ², Ayşe Cefle ³, Sema Yılmaz ⁴, Sinem Burcu Kocaer ⁵, Tuba Yüce İnel ¹, Semih Gülle ¹, Süleyman Serdar Koca ⁶, Servet Yolbaş ⁷, Mehmet Akif Öztürk ⁸, Soner Senel ⁹, Nevsun Inanc ¹⁰, Ediz Dalkılıç ¹¹, Ozgül Gunduz ¹², Abdurrahman Tufan ⁸, Servet Akar ¹³, Merih Birlik ⁵, Ismail Sari ¹, Nurullah Akkoç ¹² and Fatos Onen ¹⁴, ¹Division of Rheumatology, Dokuz Eylül University School of Medicine, İzmir, Turkey, Izmir, Turkey, ²Dokuz Eylul University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Izmir, Turkey, ³Division of Rheumatology, Kocaeli University School of Medicine, Kocaeli, Turkey, Kocaeli, Turkey, ⁴Division of Rheumatology, Selcuk University School of Medicine, Konya, Turkey, Konya, Turkey, ⁵Division of Rheumatology, Dokuz Eylül University School of Medicine, İzmir, Turkey, Turkey,Izmir, Izmir, Turkey, ⁶Fırat University School of Medicine Division of Rheumatology, Elazığ, Turkey, ⁷Division of Rheumatology, Inonu University School of Medicine, Malatya, Turkey, Malatya, Turkey, ⁸Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey, Ankara, Turkey, ⁹Division of Rheumatology, Erciyes University School of Medicine, Kayseri, Turkey, Kayseri, Turkey, ¹⁰Marmara University, Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ISTANBUL, Turkey, ¹¹Uludağ University, Bursa, Turkey, ¹²Division of Rheumatology, Celal Bayar University School of Medicine, Manisa, Turkey, Manisa, Turkey, ¹³Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ¹⁴Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey
Background/Purpose: The first symptoms of ankylosing spondylitis (AS) patients usually begin prior to 45 years, but can occur later in life. The purpose of this…
Abstract Number: 1530 • 2019 ACR/ARP Annual Meeting
Real World Effectiveness of Secukinumab in Patients with Ankylosing Spondylitis: Findings from a Recent Cross Sectional Survey of Rheumatologists and Patients in Europe
Uta Kiltz ¹, Elizabeth Holdsworth², Haijun Tian ³, Nicola Booth ⁴, Papa Anthony ⁵, Lina Helsche ⁶, Dorothy Keininger ⁶ and Philip G Conaghan ⁷, ¹Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ²Adelphi Real World, Manchester, England, United Kingdom, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Adelphi Real World, Macclesfield, England, United Kingdom, ⁶Novartis Pharma AG, Basel, Basel-Landschaft, Switzerland, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: Ankylosing spondylitis (AS) can lead to reduced physical functioning and quality of life. Secukinumab has demonstrated clinical benefits in AS patients in clinical trials1-2.…
Abstract Number: 1531 • 2019 ACR/ARP Annual Meeting
ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Underlying Rheumatoid and Psoriatic Arthritis
Lawrence Evans¹, Stacey Dillon ¹, Katherine Lewis ¹, Susan Bort ¹, Erika Rickel ¹, Jing Yang ¹, Martin Wolfson ¹, Sherri Mudri ¹, Kayla Susmilch ¹, Steven Levin ¹, Sean MacNeil ¹, Mark Rixon ¹, Jan Hillson ², Stanford Peng ¹ and Kristine Swiderek ¹, ¹Alpine Immune Sciences, Seattle, WA, ²Alpine Immune Sciences, Seattle, WI
Background/Purpose: ALPN-101 is an Fc fusion protein of a human inducible T cell costimulator ligand (ICOSL) variant immunoglobulin domain (vIgDTM) designed to simultaneously inhibit the…
Abstract Number: 1532 • 2019 ACR/ARP Annual Meeting
Withdrawal of Ixekizumab Results in Loss of Efficacy in Multiple Clinical Domains in Patients with Psoriatic Arthritis Who Had Achieved Minimal Disease Activity: Results from the SPIRIT-P3 Study
Laura Coates¹, Sreekumar Pillai ², Matthew M. Hufford ², Denise Alves ², So Young Park ², Gaia Gallo ², Beilei Wu ³, Ivo Valter ⁴, Hasan Tahir ⁵, Vinod Chandran ⁶, Arthur Kavanaugh ⁷ and Philip Mease ⁸, ¹University of Oxford, Oxford, United Kingdom, ²Eli Lilly and Company, Indianapolis, IN, ³GCE Solutions Inc., Bloomington, IL, ⁴Center for Clinical and Basic Research, Tallinn, Estonia, ⁵Department of Rheumatology, Whipps Cross University Hospital, London, United Kingdom, ⁶Division of Rheumatology, University of Toronto, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁷University of California, San Diego School of Medicine, La Jolla, CA, ⁸Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Ixekizumab (IXE), a high affinity monoclonal antibody that selectively targets interleukin-17A, has been demonstrated to improve the signs and symptoms, disease activity, and quality…
Abstract Number: 1533 • 2019 ACR/ARP Annual Meeting
The Performance Characteristics of Composite Measures Used in a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis
Laura Coates¹, Joseph Merola ², Philip Mease ³, Alexis Ogdie ⁴, Dafna Gladman ⁵, Vibeke Strand ⁶, Leonieke van Mens ⁷, Lyrica Liu ⁸, Priscilla K Yen ⁸, David Collier ⁸, Gregory Kricorian ⁸, James Chung ⁸ and Philip Helliwell ⁹, ¹University of Oxford, Oxford, United Kingdom, ²Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ³Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ⁴Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁶Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ⁷University of Amsterdam, Amsterdam, Netherlands, ⁸Amgen Inc., Thousand Oaks, CA, ⁹University of Leeds, Leeds, United Kingdom
Background/Purpose: Composite measures of disease activity are used in psoriatic arthritis (PsA), but their relative performance and contributions of individual components to overall scores are…
Abstract Number: 1534 • 2019 ACR/ARP Annual Meeting
Long-term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study
Laura Coates¹, Philip Mease ², Dafna Gladman ³, Filip Van den Bosch ⁴, Anna Rychlewska-Hanczewska ⁵, Chantal Tasset ⁶, Luc Meuleners ⁶, Mona Trivedi ⁷, Jingjing Gao ⁷, Robin Besuyen ⁶ and Philip Helliwell ⁸, ¹University of Oxford, Oxford, United Kingdom, ²Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁴Ghent University Hospital, Ghent, Belgium, ⁵5ai centrum medyczne sp. z o.o. sp.k., Poznan, Poland, Poznan, Poland, ⁶Galapagos NV, Mechelen, Belgium, ⁷Gilead Sciences Inc, Foster City, United States of America, Foster City, CA, ⁸University of Leeds, Leeds, United Kingdom
Background/Purpose: Filgotinib (FIL) is an orally administered, selective Janus Kinase 1 (JAK1) inhibitor in development for psoriatic arthritis (PsA). Efficacy and safety of FIL in…
Abstract Number: 1535 • 2019 ACR/ARP Annual Meeting
Achievement of Very Low Disease Activity and Remission Treatment Targets Is Associated with Reduced Radiographic Progression in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol
Laura Coates¹, Joseph Merola ², Arthur Kavanaugh ³, Philip Mease ⁴, Owen Davies ⁵, Oscar Irvin-Sellers ⁶, Tommi Nurminen ⁷ and Désirée van der Heijde ⁸, ¹University of Oxford, Oxford, United Kingdom, ²Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ³University of California, San Diego School of Medicine, La Jolla, CA, ⁴Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ⁵UCB Pharma, Slough, England, United Kingdom, ⁶UCB Pharma, Slough, UK, Slough, United Kingdom, ⁷UCB Pharma, Monheim, Germany, ⁸Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Several disease activity measures and thresholds have been recommended as psoriatic arthritis (PsA) treatment targets, although consensus on the most appropriate assessment tool is…
Abstract Number: 1536 • 2019 ACR/ARP Annual Meeting
A Novel MK2 Inhibitor for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases
Francisco Ramírez-Valle¹, Mary Adams ¹, Lisa Beebe ², Jian Chen ¹, Claudio Chuaqui ¹, Jamie Connarn ¹, Alan Corin ¹, Karen Dingley ¹, J. Michael Ellis ¹, Rajula Gaur ¹, Lawrence Hamann ¹, John Malona ¹, Kofi Mensah ¹ and Maria Palmisano ¹, ¹Celgene Corporation, Summit, NJ, ²Celgene Corporation, Cambridge, MA
Background/Purpose: Post-transcriptional control of cytokine and chemokine gene expression is an important checkpoint during inflammation. The MAPKAPK2 (MK2) pathway in particular is critical in regulating…
Abstract Number: 1537 • 2019 ACR/ARP Annual Meeting
Concomitant Treatment with Methotrexate Does Not Increase the Efficacy of Ustekinumab or TNF Inhibitors in Psoriatic Arthritis: Results from a Real-world, Multicenter Study
Stefan Siebert¹, Elisa Gremese ², Paul Bergmans ³, Kurt De Vlam ⁴, Beatriz Joven-Ibáñez ⁵, Gkikas Katsifis ⁶, Tatiana Korotaeva ⁷, Wim Noël ⁸, Carlo Selmi ⁹, Petros Sfikakis ¹⁰, Pavel Smirnov ¹¹, Elke Theander ¹², Michael Nurmohamed ¹³, Laure Gossec ¹⁴ and Josef Smolen ¹⁵, ¹Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Fondazione Policlinico Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy, ³Biostatistics and Medical Affairs, Janssen, Tilburg, Netherlands, ⁴University Hospitals Leuven, Leuven, Belgium, ⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Naval Hospital of Athens, Rheumatology Clinic, Athens, Greece, ⁷Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁸Biostatistics and Medical Affairs, Janssen, Brussels, Belgium, ⁹Humanitas Research Hospital, University of Milan, Milan, Italy, ¹⁰Joint Rheumatology Programme, National & Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ¹¹Biostatistics and Medical Affairs, Janssen, Moscow, Russia, ¹²Biostatistics and Medical Affairs, Janssen, Solna, Sweden, ¹³Reade and VU Rheumatology Research Department, Amsterdam, Netherlands, ¹⁴Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ¹⁵Medical University of Vienna, Vienna, Austria
Background/Purpose: The additional benefit of methotrexate as a concomitant treatment in PsA has not been fully elucidated. Observational data exist for concomitant methotrexate (MTX) use…
Abstract Number: 1538 • 2019 ACR/ARP Annual Meeting
The Effects of Apremilast Therapy on Deployability in Active Duty U.S. Army Soldiers with Plaque Psoriasis and Psoriatic Arthritis
Andrew Price¹, Vanya Wagler ², Chase Donaldson ¹ and Patrick Mastin ¹, ¹William Beaumont Army Medical Center, El Paso, TX, ²United Regional Physician Group, Wichita Falls, TX
Background/Purpose: Apremilast is a novel oral phosphodiesterase 4 inhibitor that is used for plaque psoriasis (PsO) and psoriatic arthritis (PsA). This medicine is unique in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].